Phthalates, Bisphenols, and Childhood Allergic Phenotypes: Findings from Two Birth Cohort Studies

Thomas Boissiere-O'Neill [a], Nina Lazarevic [b], Anne-Louise Ponsonby [c], Peter D. Sly [a], Aimin Chen [d], Tamara L. Blake [a], Jeffrey R. Brook [e], Cassidy Du Berry [f,g,h,i], Louise King [f, h], Piushkumar J. Mandhane [k], Theo J. Moraes [l], Elinor Simons [m], Padmaja Subbarao [e,l,n], Dwan Vilcins [a], on behalf of BIS* and CHILD investigator groups**

[a] The University of Queensland, Child Health Research Centre, The Children's Health and Environment Program QLD, 4101, Australia.
[b] National Centre for Epidemiology and Population Health, Australian National University, Canberra, ACT 2601, Australia
[c] Florey Institute of Neuroscience and Mental Health, University of Melbourne, Melbourne, VIC 3010, Australia
[d] Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, United States
[e] Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada
[f] Department of Respiratory and Sleep Medicine, Royal Children's Hospital, Parkville, Victoria, Australia
[g] Department of Paediatrics, University of Melbourne, Parkville, Victoria, Australia
[h] Respiratory Group Murdoch Children's Research Institute, Parkville, Victoria, Australia
[i] Respiratory Research@Alfred, Monash University, Melbourne, Victoria, Australia
[k] Department of Pediatrics, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada
[l] Department of Pediatrics & Translational Medicine, Hospital for Sick Children, University of Toronto, Toronto, Ontario,
Canada
[m] Department of Pediatrics and Child Health, Children's Hospital Research Institute of Manitoba, University of Manitoba, Winnipeg, Manitoba, Canada
[n] Department of Physiology, Faculty of Medicine, University of Toronto, Toronto, Canada

* BIS investigator group: Peter Vuillermin, Anne-Louise Ponsonby, Mimi L.K. Tang, Fiona Collier, Peter D. Sly, Leonard Harrison, Richard Saffery, Sarath Ranganathan, David Burgner, Toby Mansell and Martin O'Hely.
** CHILD investigator group: Padmaja Subbarao, Elinor Simons, Theo J. Moraes, Stuart E. Turvey, Piushkumar J. Mandhane and Meghan B. Azad.

Correspondence: Thomas Boissiere-O'Neill, email: t.boissiereoneill@uq.edu.au; ORCID-ID: 0000-0002-7327-3961
Keywords: Phthalates, Bisphenols, Pregnancy, Childhood, Allergies, Atopy, Lung function

Word count (full text): 4,872

Word count (abstract): 249/250

References: 73

Tables: 4

Figures: 1

ABSTRACT

Background

Phthalates and bisphenols may contribute to childhood allergic outcomes, but whether these are differentially associated with atopic or non-atopic phenotypes is uncertain. We investigated whether early-life exposure to these chemicals differentially impacts atopic and non-atopic allergic outcomes.

Methods

We used two prospective birth cohorts to investigate distinct exposure windows. The Barwon Infant Study (n = 797) measured urinary phthalate and bisphenol metabolites at 36 weeks' gestation. The Canadian Healthy Infant Longitudinal Development Study (n = 993) measured phthalate metabolites at 3, 12, and 36 months. Atopy was assessed via skin prick tests at 4-5 years. Outcomes included asthma, wheeze, eczema, and rhinitis at 4-5 years. Models were stratified by atopy. We modelled exposure mixtures using quantile G-computation and Bayesian kernel machine regression.

Results

Phthalate mixtures were associated with increased asthma risk in both exposure windows. Prenatal phthalate mixtures were more strongly associated with non-atopic asthma (adjusted risk ratio [aRR] = 1.83; 95% confidence interval [CI]: 1.10-3.04), with evidence of effect modification by atopy (p = 0.02 for interaction). Postnatal phthalate mixtures were associated with non-atopic asthma (aRR = 1.82, 95% CI: 1.19-2.78), though the association did not differ by phenotype (p = 0.45 for interaction). Phthalate mixtures showed U-shaped (prenatal) and inverse U-shaped (postnatal) associations with atopic asthma, and linear associations with non-atopic asthma. There was little evidence of associations for other allergic outcomes.

Conclusion

Early-life exposure to phthalates may differentially influence the risk of childhood atopic and non-atopic asthma. Future studies are needed to confirm these associations.

71 **HIGHLIGHTS**

72 - We used two birth cohorts to examine distinct exposure windows to phthalates.

73

74 - Pre- and postnatal phthalate exposure was associated with increased asthma risk.

75

76 - Pre- and postnatal associations with asthma differed by atopic status.

77

78 - There was little evidence of association with other allergic outcomes.

1. INTRODUCTION

Childhood asthma and allergic diseases are heterogeneous conditions, comprising different phenotypes with distinct presentations and immunological profiles (1, 2). For instance, eczema can be classified as atopic dermatitis, characterised by immunoglobulin (IgE)-mediated hypersensitivity, or non-atopic dermatitis, which lacks systemic allergic sensitisation (2). While atopy contributes to the development of asthma and other allergic conditions, its attributable fraction rarely exceeds 50% in population-based studies (3), demonstrating the heterogeneity of these conditions and the importance of distinguishing phenotypes by atopic status.

Among environmental risk factors, phthalates and bisphenols have drawn increasing concern (4). These chemicals are ubiquitous in consumer products, such as food packaging, personal care products and thermal receipts, leading to widespread population exposure in high-income countries (5). Animal and in vitro studies suggest that phthalates and bisphenols may disrupt immune function by upregulating T-helper (Th) 2 cytokines, interacting with estrogenic pathways, and inducing oxidative stress, thereby offering biologically plausible pathways for their involvement in the development of allergic outcomes (4, 6).

Epidemiological evidence also suggests associations between phthalate and bisphenol exposure and childhood asthma and eczema, with systematic reviews reporting modest effect sizes (7-9). However, findings across studies remain heterogeneous, partly due to differences in exposure timing, outcome definitions, or population susceptibility. Importantly, few studies have examined whether these chemicals are differentially associated with atopic and non-atopic phenotypes of allergic conditions. One longitudinal birth cohort study reported that specific phthalates were associated with almost a twofold increased risk of eczema in atopic boys up to five years old but not in non-atopic boys (10). In a Korean cross-sectional study, serum IgE mediated approximately 15% of the association between mono-carboxynonyl phthalate and allergic rhinitis in children aged 3–17 years (11). Similarly, a Taiwanese cohort study reported that IgE levels mediated 70% of the association between bisphenol A and physician-diagnosed asthma in six-year-old children (12)..

107 These studies suggest that atopic mechanisms may partially mediate the effects of plastic chemical
108 exposures on allergic outcomes.
109
110 However, investigating these mechanisms in early childhood is challenging, in part due to difficulties
111 in establishing accurate diagnoses. For instance, the heterogeneity of preschool asthma often leads
112 to diagnostic delays and uncertainty (13). Thus, lung function assessments offer an objective means
113 to identify and quantify early or subclinical respiratory impairment. Yet, most epidemiological studies
114 on phthalates, bisphenols, and lung function have focused on school-aged children or older
115 populations (14), leaving a gap in the understanding of early-life respiratory effects of these
116 chemicals. In preschool-aged children, tidal breathing techniques, such as multiple-breath washout
117 (MBW) and oscillometry, offer a more feasible (15), and sensitive alternative to effort-based
118 techniques, like spirometry, can be difficult to perform in pre-school aged children (16, 17)
119
120 Overall, important gaps remain. First, the extent to which associations with asthma and allergic
121 outcomes differ by atopic status is understudied. Second, only few studies have evaluated both
122 prenatal and postnatal exposures to phthalates. Third, limited work has applied lung function
123 techniques in early pre-school children to investigate subclinical respiratory effects of these
124 exposures.
125
126 In this study, we aimed to investigate whether early-life exposure to phthalates and bisphenols is
127 differentially associated with atopic and non-atopic phenotypes of asthma and allergic outcomes in
128 preschool-aged children. To address this, we leveraged two prospective birth cohorts: one in
129 Australia, assessing prenatal exposures, and one in Canada, assessing postnatal exposures. We
130 further investigated the associations between these chemicals and food allergy, as well as lung
131 function, evaluated via ventilation inhomogeneity, resistance and reactance.

132 ## 2. METHODS

133 ### 2.1. Study population

134 In this study, two birth cohorts were used to examine distinct exposure windows: the Barwon Infant
135 Study (BIS) to assess prenatal exposure to phthalates and bisphenols, and the Canadian Healthy
136 Infant Longitudinal Development (CHILD) cohort to assess postnatal exposure to phthalates.
137 Detailed descriptions of inclusion and exclusion criteria have been previously published (18, 19).
138 The Barwon Infant Study is a population-based longitudinal cohort study with 1,074 mother-infant
139 pairs recruited from the Barwon region in Victoria, Australia (18). Pregnant women at up to 28 weeks'
140 gestation were recruited if they were above 18 years, while children born <32 weeks' gestation were
141 excluded from the study. Ethics approval was granted by the Barwon Health Human Research and
142 Ethics (HREC 10/24), and parents or legal guardians provided informed consent (18). The CHILD
143 study included 3,542 infants born after 35 weeks' gestation, with pregnant mothers recruited during
144 the 2nd or 3rd trimester in four Canadian communities (Vancouver, Edmonton, Winnipeg, Toronto).
145 The Human Research Ethics Boards at the Hospital for Sick Children, McMaster University, and the
146 Universities of British Columbia, Manitoba, and Alberta approved the study, and parents or legal
147 guardians provided informed consent (19). In both cohorts, we excluded children with missing
148 exposure and outcome data (Figure S1). In the CHILD cohort, we also excluded children with only
149 one urine sample collected (N = 503) to mitigate measurement error of the exposures. The
150 methodology used in this study is shown in Figure 1 and described below.



Figure 1. Overview of the methodology used in this study

2.2. Exposure

2.2.1. Urinary metabolites measurements

Exposure was assessed using urinary metabolite concentrations in both cohorts, with prenatal exposure measured in BIS and postnatal exposure measured in CHILD. To ensure methodological comparability with previous studies from BIS and CHILD, we used the same methods for imputing values below the limit of detection (LOD) as used in those studies (20, 21).

In BIS, urine samples were collected from 842 pregnant women at approximately 36 weeks of gestation (mean = 36.0 weeks, SD = 0.7 weeks), on average three weeks before delivery (20). Samples were collected in glass or polypropylene containers, aliquoted, and stored at -80°C before shipment to the Queensland Alliance for Environmental Health Sciences for instrumental analysis (22). In CHILD, 1,578 children provided at least one urine sample at 3, 12, or 36 months of age. For non-toilet-trained children, urine was collected using absorbent pads and plastic film, then extracted and transferred to cryovials for storage at –80°C (21). Samples were analysed at AXYS Analytical Services Inc. using the Kato method (23).

170 Metabolites included in BIS were mono-methyl phthalate (MMP), mono-ethyl phthalate (MEP),
171 mono-isobutyl phthalate (MiBP), mono-n-butyl phthalate (MnBP), mono-benzyl phthalate (MBzP),
172 mono(2-ethyl-5-oxohexyl) phthalate (MEOHP), mono(2-ethyl-5-hydroxyhexyl) phthalate (MEHHP),
173 mono(5-carboxy-2-ethylpentyl) phthalate (MECPP), mono(3-carboxpropyl) phthalate (MCPP),
174 bisphenol A (BPA), bisphenol S (BPS) and bisphenol F (BPF). In CHILD, the metabolites included
175 were MEP, MiBP, MnBP, MBzP, MEHP, MEOHP, MEHHP, and MCPP.
176
177 In BIS, phthalates with values under the LOD were imputed with LOD/√2 (20), while in CHILD, robust
178 regression on order statistics was used (21). Due to bisphenols' higher proportion of values below
179 LOD, BPA was dichotomised, using the 75th percentile as a cut-off, and the 90th percentile for BPS
180 and BPF (Table S1), consistent with prior analyses in this cohort aimed at minimising bias from non-
181 detected values and accounting for potential variability across analytical methods (24). In both
182 cohorts, metabolites were corrected for specific gravity, using the Levine-Fahey equation. In BIS,
183 phthalate metabolites were further standardised for batch effect and time of day at urine collection
184 (20); this information was not available in CHILD (21). Metabolite distributions and detection
185 frequencies are shown in Table S1.
186

187 ### *2.2.2. Daily intake estimation*

188 Phthalate diester estimated daily intake was calculated to standardise metabolites for body weight,
189 considering urinary fractional excretion, molecular-weight ratio, average daily urinary output and
190 weight at sampling (20, 25):

191 $$\mathrm{EDI} = \frac{C_{adj} * UV * MW_{diester}}{FUE * W * MW_{metabolite}}$$

192 Here, C_{adj} represents the standardised metabolite concentration (µg/L), *UV* denotes the average
193 daily urine output (1.6 L during pregnancy)(20), *FUE* refers to the fraction of the metabolite excreted
194 in urine, *MW* is the molecular weight (g/mol), and *W* corresponds to the individual's body weight at
195 the time of sampling (kg). In CHILD, UV/W was estimated from the child's age at sampling (25).
196 Urinary MMP was used to estimate the daily intake of dimethyl phthalate (DMP), MEP for diethyl
197 phthalate (DEP), MnBP for di-n-butyl phthalate (DnBP), MiBP for di-isobutyl phthalate (DiBP), MBzP

198 for butyl benzyl phthalate (BBzP), and MEHP, MEHHP, MEOHP, and MECPP for di(2-ethylhexyl)
199 phthalate (DEHP). DiBP and DnBP were summed to derive the total dibutyl phthalate exposure
200 (DBP). In CHILD, the daily intake for each phthalate was estimated at 3, 12 and 36 months, and the
201 per-child average was used to represent exposure from infancy through early childhood. Since
202 MCPP is a non-specific metabolite of high-molecular-weight phthalates (26), we did not calculate its
203 daily intake. In BIS, measurements at 36 weeks' gestation are referred to as *prenatal exposure*,
204 whereas in CHILD, the average across time points is referred to as *postnatal exposure*.
205

206 ## 2.3. Outcomes

207 In BIS, all outcomes were assessed at the age of four, whereas in CHILD, assessments were
208 conducted at the age of five.

209 ### *2.3.1. Primary outcomes*

210 Skin prick testing was employed to determine atopic status, defined as the presence of a wheal at
211 least 3 mm larger than the negative control for any tested allergen, in the presence of a positive
212 control ≥ 3 mm and a negative control ≤ 3 mm (27). The list of allergens tested in each cohort is
213 provided in Table S2. In BIS, asthma was identified through parental report ("*Has your child ever*
214 *had asthma?*"), and wheeze was assessed with the question, "*Has your child had wheezing or*
215 *whistling from the chest in the last 12 months?*". Eczema was defined using the modified UK Working
216 Party criteria (28), and rhinitis was assessed through the question, "*Has your child ever had hay*
217 *fever?*". In CHILD, asthma, eczema, and rhinitis were assessed by subspecialist paediatricians and
218 classified as "definite", "possible," or "no" (29). Only children with a "definite" diagnosis were
219 considered cases. Wheeze was defined based on a positive response to the question, "*In the last*
220 *year, has your child had a wheezing noise (whistling sound) coming from his/her chest either WITH*
221 *a cold or WITHOUT a cold?*".
222

223 ### *2.3.2. Secondary outcomes*

224 To further investigate IgE-mediated outcomes, we investigated the association between prenatal
225 exposures and food allergy in the BIS cohort. Food allergy was assessed at the one-year follow-up

226 using a hospital-based open food challenge (27). Challenge-proven food allergy data was not
227 available in CHILD. To assess early-life lung function, we evaluated ventilation inhomogeneity and
228 lung volumes using multiple-breath washout (MBW) and reactance and resistance using
229 oscillometry. MBW is a non-invasive tidal-breathing technique that measures ventilation distribution
230 by quantifying the efficiency with which an inert gas is cleared from the lungs (30, 31). The lung
231 clearance index ($LCI_{2.5}$) indicates the number of lung volume turnovers necessary to expel the inert
232 gas. Functional residual capacity (FRC), the volume of air remaining in the lungs after a normal
233 expiration, is also derived from this test. Oscillometry, in contrast, applies external pressure
234 oscillations at multiple frequencies during tidal breathing to assess airway mechanics (32). It
235 quantifies respiratory impedance, which consists of resistance (R) and reactance (X). Resistance
236 reflects energy loss due to airflow obstruction, while reactance captures the elastic and inertial
237 properties of the respiratory system.
238
239 In both cohorts, MBW was performed using 2.5% nitrogen (N_2) and an ultrasonic flowmeter
240 (Exhalyzer D, Ecomedics, Duernten, Switzerland), with data analysed in Spiroware 3.3.1,
241 incorporating cross-sensitivity corrections for the oxygen and carbon dioxide sensors (33). Testing
242 was performed and analysed following current guidelines (30, 31). In BIS, lung function was also
243 assessed with intrabreath oscillometry using equipment provided by the INCIRCLE collaboration
244 (34). Oscillatory signals at 10 Hz were applied every 0.1 seconds during undisturbed tidal breathing,
245 with impedance measured at end-inspiration and end-expiration (35). In CHILD, spectral oscillometry
246 was performed using the TremoFlo system (THORASYS Thoracic Medical Systems Inc., Montreal,
247 Canada), which delivered oscillations across a frequency range of 5 to 37 Hz (19). Due to differences
248 in oscillometry techniques and to improve comparability between cohorts, resistance and reactance
249 values in BIS were calculated as the mean of end-inspiratory and end-expiratory values at 10 Hz
250 (R10 and X10), while in CHILD, values at 11 Hz (R11 and X11) were used.

251 ## 2.4. Sociodemographic and risk factors

252 We first selected variables using a Directed Acyclic Graph (Figure S2), informed by prior knowledge
253 and previous studies (4, 7). Definitions and cohort availability of each variable are shown in Table
254 S3. Sociodemographic factors included maternal age at conception, marital status, remoteness area,
255 caregiver education, household income, and child's ethnicity. The Socio-Economic Indexes for Areas
256 (SEIFA) Index of Relative Socioeconomic Disadvantage, a composite measure of area-based
257 socioeconomic status, was also included as tertiles in BIS (36). Perinatal and birth characteristics
258 included year and season of birth, birthweight, sex, and breastfeeding duration. Family and
259 environmental factors included family history of asthma, tobacco smoke exposure during pregnancy,
260 smoking inside the house during childhood, home renovation, household size, and pet ownership.
261 In BIS, maternal diet during pregnancy was assessed using a food frequency questionnaire and
262 principal component analysis (20, 37). This analysis identified three dietary patterns: (i) a modern
263 healthy diet, (ii) a western unhealthy diet, and (iii) a traditional Anglo-Saxon diet. Factor scores were
264 categorised into tertiles (low, medium, high), reflecting diet adherence. We also incorporated a
265 volatile household product use score in BIS, based on the frequency of household product use during
266 pregnancy, as previously developed by the Avon Longitudinal Study of Parents And Children
267 (ALSPAC) cohort (20, 38).

268

269 ## 2.5. Statistical analysis

270 Population characteristics and exposure concentrations were summarised using descriptive
271 statistics. Since exposure variables followed a log-normal distribution, we applied a log2
272 transformation. Missing covariate data were imputed using multiple imputation by chained equations,
273 with five datasets and 20 iterations (39). Given differences in exposure measurements and outcome
274 assessments between BIS and CHILD, estimates were not pooled between cohorts.

275 ### *2.5.1. Atopic and non-atopic phenotypes*

276 To evaluate potential nonlinearity, we first fitted generalised linear models with and without restricted
277 cubic spline models (three knots at the 10th, 50th, and 90th percentiles), selecting the best-fit model
278 using the Akaike Information Criterion (AIC) (40). Prenatal DEP in BIS, showed evidence of
279 nonlinearity across several outcomes (Figure S3). We followed a systematic approach to build the
280 multivariable models (41). First, we screened variables identified in the DAG as potential
281 confounders. Second, variables that altered the exposure-outcome estimate by 10% or more in
282 bivariable models were retained (41). Variables on the causal pathway (i.e., mediators) were
283 excluded from adjustment. Associations between each exposure and binary outcomes were
284 estimated using modified Poisson regression with robust standard errors to estimate crude and
285 adjusted risk ratios (RR) with 95% confidence intervals (95% CI) (42). Continuous outcomes were
286 scaled to enable between-model comparison, and associations were estimated with linear
287 regression. We considered atopy and allergic outcomes separately and conducted stratified
288 analyses by atopy, as previously recommended (43). Thus, we introduced interaction terms between
289 each exposure and atopy to formally test for effect measure modification and derived phenotype-
290 specific estimates, using the *marginaleffects* package (44). To estimate the combined effect of
291 exposures, we applied quantile g-computation, showing RR and 95% CI associated with a one-
292 quartile increase in all exposures (45). For consistency, the mixture analysis included only chemicals
293 measured in both cohorts, excluding DMP and bisphenols from BIS. Interaction terms between the
294 exposure mixture and atopy were added using the qgcompint package (46). Weights were averaged
295 across imputed datasets to obtain pooled weights given the use of multiple imputation.
296

297 ### *2.5.2. Supplementary analyses*

298 Outcome antecedents that did not substantially alter exposure-outcome associations were added to
299 assess potential residual confounding. To confirm the results of quantile G-computation, we ran
300 Bayesian Kernel Machine Regression (BKMR) on primary outcomes, for 50,000 iterations, stratified
301 by atopic status. This method employs a Gaussian kernel function to estimate exposure effects by
302 measuring distances between individuals in the exposure space. Prior distributions for the smoothing

303 parameter (r) were identified using frequentist kernel machine regression, and uninformative priors
304 were used for the remaining parameters in the final model (47). We adjusted the Metropolis-Hastings
305 parameters (r_{jump}, λ_{jump}) to achieve acceptance rates of 20-40%. BKMR models were fitted within
306 each imputed dataset and pooled using Rubin's rule. Because skin prick test results can be
307 influenced by factors such as pet ownership and allergen avoidance, we conducted a sensitivity
308 analysis focusing on house dust mite and grass pollen from skin prick testing (Table S2), as these
309 allergens are ubiquitous and less affected by modifiable factors (48, 49). To further avoid
310 confounding by concomitant sensitisation, we used mutually exclusive categories: no sensitisation
311 to HDM or grass (reference), sensitisation to HDM only, sensitisation to grass only, and sensitisation
312 to both HDM and grass (50).

313 # 3. RESULTS

314 ## 3.1. Sample characteristics

315 A total of 797 children from BIS and 993 from CHILD were included (Figure S1). There were no
316 substantial differences in outcome and exposure distributions between study samples and full
317 cohorts (Table S4-S5). Out of 467 children in BIS who underwent skin prick testing, 28.7% (n = 134)
318 were atopic. In CHILD, out of 937 children, 13.1% (n = 123) were atopic. In both cohorts, atopic
319 children were more likely to be males, to have a family history of asthma, and had higher outcome
320 prevalence compared to non-atopic children (Table 1-2).) BIS had a lower proportion of university-
321 educated caregivers, a lower rate of tobacco smoke exposure during pregnancy, smaller
322 households, and a higher proportion of Caucasian/White children compared to CHILD. Overall,
323 allergic outcomes were more prevalent in BIS compared to CHILD, although the proportion of
324 children with eczema was similar between cohorts.

Table 1. Descriptive characteristics of the Barwon Infant Study

	Atopy subcohort (N = 467) Non-atopic (N = 333)		Atopic (N = 134)		**Study sample (N = 797)**	
	N	n (%) mean ± SD	N	n (%) mean ± SD	N	n (%) mean ± SD
Year of birth	333		134		797	
2010-2011		114 (34.2%)		41 (30.6%)		297 (37.3%)
2012		118 (35.4%)		52 (38.8%)		285 (35.8%)
2013		101 (30.3%)		41 (30.6%)		215 (27.0%)
Season of birth	333		134		797	
Autumn		74 (22.2%)		31 (23.1%)		194 (24.3%)
Spring		73 (21.9%)		35 (26.1%)		169 (21.2%)
Summer		81 (24.3%)		31 (23.1%)		189 (23.7%)
Winter		105 (31.5%)		37 (27.6%)		245 (30.7%)
Male	333	156 (46.8%)	134	88 (65.7%)	797	418 (52.4%)
Breastfeeding duration (weeks)	197	25.4 ± 16.7	81	24.8 ± 17.6	483	24.5 ± 17.1
Birthweight (kg)	333	3.59 ± 0.50	134	3.6 ± 0.4	797	3.6 ± 0.5
Maternal age at conception	333	32.6 ± 4.31	134	33.0 ± 4.2	797	32.5 ± 4.5
Lone parenthood	332	9 (2.7%)	134	4 (3.0%)	794	22 (2.8%)
Caucasian/white	330	256 (77.6%)	133	108 (81.2%)	789	607 (76.9%)
Living in a major city	330	235 (71.2%)	134	107 (79.9%)	784	560 (71.4%)
Caregiver university educated	332	192 (57.8%)	134	74 (55.2%)	796	438 (55.0%)
SEIFA tertiles	333		134		796	
1		78 (23.4%)		37 (27.6%)		180 (22.6%)
2		58 (17.4%)		29 (21.6%)		155 (19.5%)
3		197 (59.2%)		68 (50.7%)		461 (57.9%)
Household income	325		132		778	
< 75, 000 AUD		87 (26.8%)		35 (26.5%)		204 (26.2%)
75,000 – 99,999 AUD		81 (24.9%)		33 (25.0%)		199 (25.6%)
100,000 – 149,999 AUD		119 (36.6%)		46 (34.8%)		278 (35.7%)
≥ 150,000 AUD		38 (11.7%)		18 (13.6%)		97 (12.5%)
Family history of asthma	332	148 (44.6%)	134	87 (64.9%)	796	393 (49.4%)
Tobacco smoke exposure during pregnancy	331	33 (10.0%)	133	15 (11.3%)	791	90 (11.4%)
Smoking inside the house (4 years)	330	0 (0.0%)	132	1 (0.8%)	689	1 (0.1%)
House renovation during pregnancy	320	206 (64.4%)	128	79 (61.7%)	758	481 (63.5%)
Household size	333		131		794	
2		134 (40.2%)		50 (38.2%)		318 (40.1%)
3		119 (35.7%)		53 (40.5%)		288 (36.3%)
≥ 4		80 (24.0%)		28 (21.4%)		188 (23.7%)
Pet ownership during pregnancy	332	242 (72.9%)	134	94 (70.1%)	795	584 (73.5%)
Volatile household product score	236	8.8 ± 5.1	97	8.7 ± 4.9	534	9.3 ± 5.3
Functional residual capacity (litres)	126	0.57 ± 0.10	45	0.56 ± 0.09	205	0.57 ± 0.10
Lung clearance index (turnovers)	126	6.23 ± 0.44	45	6.24 ± 0.38	205	6.23 ± 0.42
Resistance at 10Hz ($cmH_2O.s/L$)	214	8.34 ± 1.85	89	8.20 ± 2.05	393	8.27 ± 1.90
Reactance at 10 Hz ($cmH_2O.s/L$)	214	-1.61 ± 1.21	89	-1.57 ± 1.07	393	-1.55 ± 1.17
Food allergy (1 year)	318	7 (2.2%)	121	32 (26.4%)	689	53 (7.7%)
Asthma (4 years)	333	40 (12.0%)	133	42 (31.6%)	761	117 (15.4%)
Wheeze (4 years)	331	56 (16.9%)	134	46 (34.3%)	767	161 (21.0%)
Eczema (4 years)	318	38 (11.9%)	122	32 (26.2%)	729	99 (13.6%)
Rhinitis (4 years)	330	27 (8.2%)	133	31 (23.3%)	695	87 (12.5%)

Abbreviations: SEIFA: Socio-Economic Indexes for Areas

Table 2. Descriptive characteristics of the Canadian Healthy Infant Longitudinal Development Study

	Atopy subcohort (N = 937)				**Study sample (N = 993)**	
	Non-atopic (N = 814)		Atopic (N = 123)			
	N	n (%) mean ± SD	N	n (%) mean ± SD	N	n (%) mean ± SD
Centre of recruitment	814		123		993	
Edmonton		148 (18.2%)		27 (22.0%)		180 (18.1%)
Toronto		122 (15.0%)		24 (19.5%)		172 (17.3%)
Vancouver		227 (27.9%)		51 (41.5%)		296 (29.8%)
Winnipeg		317 (38.9%)		21 (17.1%)		345 (34.7%)
Year of birth	814		123		993	
2009-2010		378 (46.4%)		62 (50.4%)		461 (46.4%)
2011		436 (53.6%)		61 (49.6%)		532 (53.6%)
Season of birth	814		123		993	
Autumn		162 (19.9%)		22 (17.9%)		201 (20.2%)
Spring		246 (30.2%)		28 (22.8%)		286 (28.8%)
Summer		247 (30.3%)		46 (37.4%)		310 (31.2%)
Winter		159 (19.5%)		27 (22.0%)		196 (19.7%)
Male	814	450 (55.3%)	123	73 (59.3%)	993	550 (55.4%)
Birthweight	789	3.46 ± 0.49	120	3.45 ± 0.44	964	3.5 ± 0.5
Breastfeeding duration (weeks)	814	44.36 ± 26.69	123	41.78 ± 26.73	993	44.3 ± 26.6
Maternal age at conception (years)	795	32.16 ± 4.41	121	33.25 ± 4.80	971	32.3 ± 4.5
Lone parenthood	797	40 (5.0%)	122	5 (4.1%)	975	46 (4.7%)
Child ethnicity	814		123		993	
Caucasian/white		608 (74.7%)		64 (52.0%)		704 (70.9%)
Multiracial		116 (14.3%)		26 (21.1%)		153 (15.4%)
Other		90 (11.1%)		33 (26.8%)		136 (13.7%)
Caregiver university educated	814	669 (82.2%)	123	97 (78.9%)	993	818 (82.4%)
Household income	725		106		879	
< 80,000 CAD		238 (32.8%)		33 (31.1%)		280 (31.9%)
80,000 – 149,999 CAD		322 (44.4%)		45 (42.5%)		388 (44.1%)
≥ 150,000 CAD		165 (22.8%)		28 (26.4%)		211 (24.0%)
Family history of asthma	809	167 (20.6%)	123	38 (30.9%)	988	218 (22.1%)
Maternal smoke exposure during pregnancy	798	133 (16.7%)	122	18 (14.8%)	976	155 (15.9%)
Smoking inside the house (5 years)	644	5 (0.8%)	101	0 (0.0%)	792	6 (0.8%)
House renovations (5 years)	794	260 (32.7%)	116	31 (26.7%)	965	305 (31.6%)
Household size (4+ vs < 4)	794	440 (55.4%)	116	74 (63.8%)	965	541 (56.1%)
Pet ownership (5 years)	696	289 (41.5%)	102	37 (36.3%)	848	339 (40.0%)
Functional residual capacity (litres)	43	0.67 ± 0.15	5	0.77 ± 0.14	54	0.67 ± 0.15
Lung clearance index (turnovers)	43	7.37 ± 0.97	5	6.77 ± 0.29	54	7.27 ± 0.94
Resistance at 11Hz ($cmH_2O.s/L$)	111	10.44±2.13	23	10.59±2.77	154	10.50 ± 2.25
Reactance at 11Hz ($cmH_2O.s/L$)	111	-2.56±1.64	23	-2.74±1.56	154	-2.66 ± 1.64
Asthma (5 years)	814	44 (5.4%)	123	15 (12.2%)	976	62 (6.4%)
Wheeze (5 years)	697	58 (8.3%)	110	17 (15.5%)	857	79 (9.2%)
Eczema (5 years)	698	97 (13.9%)	109	28 (25.7%)	857	132 (15.4%)
Rhinitis (5 years)	814	44 (5.4%)	123	28 (22.8%)	976	77 (7.9%)

330 Relative to body weight, children in CHILD had higher estimated daily intakes than pregnant women
331 in BIS, except for DEP (Table 3). In both cohorts, the exposure distributions did not differ substantially
332 between atopic and non-atopic children.

333 Table 3. Exposure distributions stratified by atopic status [a]

	BIS Median [IQR] or N (%)				CHILD Median [IQR] or N (%)			
	Overall (N = 797)	**Non-atopic (N = 298)**	**Atopic (N = 111)**	**p [b]**	**Overall (N = 993)**	**Non-atopic (N = 814)**	**Atopic (N = 123)**	**p [b]**
DMP (µg/kg/day)	0.05 [0.05]	0.05 [0.05]	0.05 [0.06]	0.62	-	-	-	-
DEP (µg/kg/day)	1.37 [2.84]	1.30 [3.06]	1.38 [2.81]	0.92	1.20 [1.38]	1.20 [1.50]	1.21 [1.19]	0.83
DBP (µg/kg/day)	1.87 [1.73]	1.90 [1.80]	1.91 [1.95]	0.73	2.53 [2.05]	2.52 [1.99]	2.71 [2.48]	0.17
BBzP (µg/kg/day)	0.18 [0.25]	0.18 [0.24]	0.18 [0.24]	0.25	0.47 [0.81]	0.49 [0.83]	0.53 [0.89]	0.80
DEHP (µg/kg/day)	1.54 [1.28]	1.58 [1.19]	1.49 [1.10]	0.50	7.02 [5.58]	6.95 [5.29]	6.96 [6.34]	0.36
MCPP (µg/L)	1.38 [2.36]	1.42 [2.69]	1.49 [2.30]	0.72	1.66 [1.37]	1.65 [1.40]	1.71 [1.22]	0.84
BPA in top quartile	201 (25.2%)	90 (27.0%)	27 (47.7%)	0.12	-	-	-	-
BPS in top decile	79 (9.9%)	41 (12.3%)	10 (7.5%)	0.13	-	-	-	-
BPF in top decile	81 (10.2%)	36 (10.8%)	16 (11.9%)	0.73	-	-	-	-

334 [a] *In BIS, 467 children underwent skin prick tests. In CHILD, 937 underwent skin prick tests*
335 [b] *p-values obtained with Wilcoxon rank-sum test for phthalates and Chi-squared test for bisphenols*
336

337 ### 3.2. Atopic and non-atopic phenotypes

338 In BIS, prenatal exposure to BBzP was inversely associated with atopy at age four (RR = 0.87; 95%
339 CI: 0.79–0.97; Table S6). In contrast, no associations were observed between postnatal phthalate
340 exposure and atopy at age five in the CHILD cohort.

341

342 Prenatal exposure to BPA in BIS was inversely associated with wheeze (RR = 0.64; 95% CI: 0.44–
343 0.94), but no other associations were found with overall outcomes at age four (Table 4). In CHILD,
344 postnatal DBP was associated with an increased risk of asthma at age five (RR = 1.40; 95% CI:
345 1.10–1.77). Postnatal DEP (RR = 1.20; 95%CI: 1.07–1.35) and DBP (RR = 1.40; 95% CI: 1.11–1.76)
346 were also associated with a higher risk of wheezing. The overall postnatal phthalate mixture was
347 positively associated with asthma (RR = 1.69; 95% CI: 1.20–2.39) and wheeze (RR = 1.53; 95% CI:
348 1.11–2.10), with DEP and DBP identified as the most influential components (Figure S4). In addition,
349 postnatal BBzP was associated with eczema (RR = 1.15; 95% CI: 1.03–1.28). Crude estimates are
350 shown in Table S7.

There was some evidence of effect measure modification by atopy in BIS. The association between prenatal MCPP levels and asthma differed by atopic status (p = 0.02 for interaction), with stronger estimates observed for non-atopic asthma (RR = 1.12; 95% CI: 0.99–1.27) than for atopic asthma (RR = 0.93; 95% CI: 0.84–1.03). Similarly, the prenatal phthalate mixture was more strongly associated with non-atopic asthma (RR = 1.83; 95% CI: 1.10–3.04) than with atopic asthma (RR = 0.94; 95% CI: 0.78–1.15; p = 0.02 for interaction). In contrast, prenatal BPS showed a stronger association with atopic asthma (RR = 1.89; 95% CI: 0.68–5.24; p = 0.05 for interaction), while prenatal BPF showed a stronger association with atopic wheeze (RR = 1.87; 95% CI: 0.95–3.68; p = 0.08 for interaction).

In the CHILD cohort, postnatal exposure to DBP (RR = 1.49; 95% CI: 1.13–1.96), BBzP (RR = 1.24; 95% CI: 1.00–1.54), and the overall phthalate mixture (RR = 1.82; 95% CI: 1.19–2.78) was associated with an increased risk of non-atopic asthma, but not atopic asthma. However, these associations did not differ substantially from those observed for atopic asthma (p for interaction = 0.19 for DBP, 0.83 for BBzP, 0.45 for the mixture). A similar pattern was observed for non-atopic wheeze, with positive associations for DEP (RR = 1.21; 95% CI, 1.07–1.37; p = 0.99 for interaction), DBP (RR = 1.52; 95% CI, 1.16–2.00; p = 0.14 for interaction), MCPP (RR = 1.31; 95% CI, 1.03–1.67; p = 0.12 for interaction) and the overall phthalate mixture (RR = 1.67; 95% CI: 1.16–2.40, p = 0.38 for interaction).

Table 4. Adjusted risk ratios (and 95% confidence intervals) for outcomes associated with phthalates and bisphenols.

	BIS (Prenatal exposure) [a]			CHILD (Postnatal exposure) [b]		
Asthma	**Overall (N = 761)**	**Non-atopic (N = 333)**	**Atopic (N = 133)**	**Overall (N = 976)**	**Non-atopic (N = 814)**	**Atopic (N = 123)**
DMP	0.99 (0.86-1.14)	1.10 (0.85-1.43)	0.93 (0.77-1.14)	-	-	-
DEP	1.00 (0.91-1.11)	1.02 (0.87-1.20)	0.99 (0.84-1.16)	1.14 (0.99-1.31)	1.14 (0.98-1.32)	1.33 (0.84-2.09)
DBP	1.02 (0.86-1.21)	1.14 (0.83-1.55)	0.93 (0.70-1.24)	1.40 (1.10-1.77)	1.49 (1.13-1.96)	1.06 (0.69-1.64)
BBzP	1.00 (0.91-1.11)	1.17 (0.97-1.41)	1.07 (0.87-1.30)	1.20 (0.99-1.45)	1.24 (1.00-1.54)	1.19 (0.82-1.71)
DEHP	0.93 (0.78-1.12)	1.05 (0.78-1.42)	0.88 (0.67-1.17)	1.28 (0.99-1.65)	1.30 (0.93-1.80)	1.20 (0.74-1.95)
MCPP	0.99 (0.92-1.06)	1.12 (0.99-1.27) *	0.93 (0.84-1.03) *	1.32 (1.05-1.66)	1.31 (0.98-1.74)	1.24 (0.81-1.91)
BPA [c]	0.82 (0.54-1.26)	1.19 (0.61-2.34)	0.97 (0.46-2.02)	-	-	-
BPS [c]	0.77 (0.40-1.46)	0.34 (0.08-1.42) †	1.89 (0.68-5.24) †	-	-	-
BPF [c]	1.32 (0.79-2.20)	1.18 (0.48-2.94)	1.98 (0.91-4.32)	-	-	-
QG-comp [d]	0.99 (0.78-1.26)	1.83 (1.10-3.04) *	0.94 (0.78-1.15) *	1.69 (1.20-2.39)	1.82 (1.19-2.78)	1.39 (0.78-2.49)
Wheeze	**Overall (N = 767)**	**Non-atopic (N = 331)**	**Atopic (N = 134)**	**Overall (N = 857)**	**Non-atopic (N = 697)**	**Atopic (N = 110)**
DMP	0.98 (0.87-1.11)	1.05 (0.83-1.32)	0.96 (0.80-1.15)	-	-	-
DEP	0.98 (0.91-1.06)	1.02 (0.89-1.17)	0.90 (0.79-1.03)	1.20 (1.07-1.35)	1.21 (1.07-1.37)	1.21 (0.77-1.90)
DBP	0.94 (0.82-1.08)	0.97 (0.77-1.24)	1.01 (0.78-1.32)	1.40 (1.11-1.76)	1.52 (1.16-2.00)	1.05 (0.69-1.58)
BBzP	0.98 (0.91-1.07)	1.03 (0.89-1.21)	1.07 (0.91-1.26)	1.08 (0.92-1.27)	1.06 (0.89-1.27)	1.27 (0.89-1.82)
DEHP	1.00 (0.87-1.14)	1.01 (0.81-1.24)	1.13 (0.84-1.50)	1.08 (0.84-1.39)	1.15 (0.85-1.55)	0.96 (0.56-1.65)
MCPP	0.99 (0.93-1.04)	0.97 (0.88-1.06)	1.04 (0.93-1.16)	1.18 (0.95-1.47)	1.31 (1.03-1.67)	0.87 (0.55-1.38)
BPA [c]	0.64 (0.44-0.94)	0.65 (0.34-1.24)	0.85 (0.41-1.77)	-	-	-
BPS [c]	0.87 (0.53-1.45)	0.54 (0.19-1.56)	1.06 (0.35-3.22)	-	-	-
BPF [c]	0.90 (0.56-1.45)	0.73 (0.31-1.72) †	1.87 (0.95-3.68) †	-	-	-
QG-comp [d]	0.94 (0.78-1.15)	1.08 (0.69-1.67)	1.00 (0.56-1.79)	1.53 (1.11-2.10)	1.67 (1.16-2.40)	1.18 (0.58-2.40)
Eczema	**Overall (N = 729)**	**Non-atopic (N = 298)**	**Atopic (N = 122)**	**Overall (N = 857)**	**Non-atopic (N = 698)**	**Atopic (N = 109)**
DMP	1.05 (0.87-1.25)	1.15 (0.89-1.49)	1.04 (0.76-1.41)	-	-	-
DEP	1.02 (0.92-1.14)	1.02 (0.87-1.21)	1.07 (0.89-1.29)	0.96 (0.85-1.09)	0.97 (0.83-1.12)	0.92 (0.66-1.27)
DBP	0.94 (0.79-1.12)	0.91 (0.68-1.24)	0.95 (0.69-1.32)	0.96 (0.79-1.18)	0.95 (0.74-1.20)	0.82 (0.59-1.14)
BBzP	1.02 (0.90-1.15)	1.01 (0.81-1.25)	1.13 (0.89-1.43)	1.15 (1.03-1.28)	1.12 (0.98-1.27)	1.19 (0.94-1.49)
DEHP	0.91 (0.73-1.12)	0.90 (0.61-1.33)	1.07 (0.74-1.53)	0.97 (0.79-1.18)	0.98 (0.78-1.22)	0.83 (0.47-1.46)
MCPP	1.05 (0.98-1.14)	1.11 (0.97-1.27)	1.01 (0.87-1.16)	1.04 (0.89-1.23)	1.06 (0.88-1.28)	1.05 (0.71-1.53)
BPA [c]	0.65 (0.39-1.10)	0.76 (0.35-1.66)	0.48 (0.13-1.78)	-	-	-
BPS [c]	0.86 (0.45-1.66)	1.64 (0.73-3.71)	0.37 (0.04-3.79)	-	-	-
BPF [c]	0.38 (0.15-1.00)	0.21 (0.03-1.64)	0.46 (0.11-1.86)	-	-	-
QG-comp [d]	0.99 (0.76-1.29)	1.04 (0.63-1.72)	1.06 (0.54-2.09)	1.05 (0.84-1.30)	0.97 (0.76-1.24)	1.10 (0.69-1.76)
Rhinitis	**Overall (N = 695)**	**Non-atopic (N = 330)**	**Atopic (N = 133)**	**Overall (N = 976)**	**Non-atopic (N = 814)**	**Atopic (N = 123)**
DMP	1.08 (0.91-1.29)	1.05 (0.86-1.28)	1.09 (0.76-1.56)	-	-	-
DEP	0.98 (0.87-1.11)	0.98 (0.81-1.19)	0.88 (0.73-1.06)	0.91 (0.75-1.10)	0.83 (0.65-1.05)	1.09 (0.72-1.67)
DBP	1.05 (0.85-1.29)	1.28 (0.88-1.86)	1.10 (0.70-1.73)	1.08 (0.81-1.43)	1.11 (0.81-1.51)	0.89 (0.54-1.45)
BBzP	1.09 (0.95-1.25)	1.18 (0.95-1.46)	1.21 (0.94-1.56)	1.02 (0.85-1.22)	0.90 (0.72-1.14) †	1.20 (0.90-1.59) †
DEHP	1.07 (0.89-1.29)	1.15 (0.92-1.44)	1.23 (0.87-1.75)	1.12 (0.86-1.47)	1.12 (0.80-1.57)	0.99 (0.59-1.63)
MCPP	1.06 (0.97-1.15)	1.11 (0.96-1.29)	1.06 (0.90-1.25)	1.16 (0.91-1.49)	0.98 (0.66-1.45)	1.28 (0.83-1.97)
BPA [c]	0.73 (0.43-1.24)	0.72 (0.28-1.81)	1.12 (0.44-2.88)	-	-	-
BPS [c]	0.93 (0.45-1.92)	1.33 (0.46-3.80)	1.28 (0.37-4.50)	-	-	-
BPF [c]	1.35 (0.73-2.52)	1.67 (0.64-4.38)	1.10 (0.32-3.76)	-	-	-
QG-comp [d]	1.13 (0.84-1.53)	1.44 (0.77-2.69)	1.08 (0.50-2.32)	1.05 (0.76-1.45)	0.84 (0.52-1.37)	1.20 (0.77-1.87)

** $p < 0.05$ for interaction. † $0.05 \leq p < 0.10$ for interaction.*

[a] Adjusted for age, sex, ethnicity, year and season of birth, family history of asthma, household income, SEIFA, household size, western diet during pregnancy, volatile household product score, and tobacco smoke exposure during pregnancy. [b] Adjusted for centre of recruitment, age, sex, ethnicity, year and season of birth, family history of asthma, pet ownership at age five, household income, household size, breastfeeding duration and tobacco smoke exposure during pregnancy. [c] BPA in top quartile; BPS and BPF in top decile. [d] Quantile g-computation estimates reflect the effect of a simultaneous one-quartile increase in DEP, DBP, BBzP, DEHP, and MCPP.

380 ### 3.3. Supplementary analysis

381 Adjustment for additional covariates did not substantially change the estimates from the main
382 analysis (Table S8). Results from BKMR were generally consistent with quantile G-computation
383 (Figure S5-S6). However, prenatal and postnatal phthalate mixtures exhibited non-linear
384 associations with atopic asthma. Specifically, the prenatal phthalate mixture demonstrated a U-
385 shaped dose-response, while the postnatal mixture followed an inverted U-shaped relationship. The
386 non-linear association observed with prenatal exposure was mainly driven by DEP, which was
387 identified in our spline analyses (Figure S3).

388

389 In BIS, prenatal BPA was associated with a reduced risk of food allergy at one year of age (Table
390 S9). Prenatal DMP exposure was inversely associated with sensitisation to both house dust mite
391 and grass pollen, whereas postnatal MCCP showed a positive association (RR = 2.31; 95% CI: 1.11–
392 4.85; Table S10).

393

394 Regarding lung function outcomes, the prenatal phthalate mixture in BIS, was associated with
395 increased FRC in atopic children (β = 0.27 SD; 95% CI: 0.02, 0.53), but tended to reduce FRC in
396 non-atopic children (p = 0.003 for interaction; Table S11). The mixture was also associated with
397 reduced resistance exclusively in atopic children (β = -0.34 SD; 95% CI: -0.58, -0.09; p = 0.02 for
398 interaction). Additionally, prenatal BPF exposure tended to increase airway resistance in atopic
399 children and decrease resistance in non-atopic children (p = 0.04 for interaction). Prenatal DEP
400 exposure in BIS was associated with decreased resistance (p < 0.001 for interaction) and increased
401 reactance only among atopic children (p = 0.04 for interaction), although spline models suggested
402 non-linear dose–response relationships (Figure S3).

403 ## 4. DISCUSSION

404 Prenatal and early childhood urinary concentrations of phthalate metabolites, measured in two
405 separate cohorts, were associated with an increased risk of asthma in preschool-aged children.
406 Associations between phthalate mixtures and asthma varied by atopic status across both exposure
407 windows: mixtures showed a linear relationship with non-atopic asthma and non-linear associations
408 with atopic asthma. Furthermore, prenatal exposure to BPF showed stronger associations with
409 wheeze and airway resistance in atopic children, compared to non-atopic children. There was limited
410 evidence of associations for other allergic outcomes. Overall, this study suggests that early-life
411 exposure to phthalates may differentially influence asthma phenotypes, with little evidence of
412 consistent associations with other allergic outcomes.
413
414 Few studies have investigated whether phthalate exposure may differentially influence atopic versus
415 non-atopic phenotypes of childhood allergic conditions. Two European birth cohorts reported
416 associations between prenatal DEHP metabolites and increased risk of atopic eczema, only in boys
417 (10, 51). Differences in outcome definitions may explain the lack of replication in our study. Those
418 studies assessed eczema over a broader age range (from birth to 4–5 years), whereas we assessed
419 outcomes at a single time point. Furthermore, atopy was defined using total IgE, whereas we used
420 SPT, which generally shows better diagnostic performance for early childhood allergies (52)
421 Although we did not stratify our analyses by sex, future studies should investigate potential sex-
422 specific susceptibilities for IgE-mediated outcomes. Our results for non-atopic asthma are in line with
423 findings from the ALSPAC cohort, which reported that higher use of household chemical products
424 during pregnancy, many of which contain phthalates (20, 53), was associated with an increased risk
425 of non-atopic wheeze, but not atopic wheeze (54). Furthermore, other environmental chemicals,
426 such as poly- and perfluoroalkyl substances and polycyclic aromatic hydrocarbons, have been
427 associated with non-atopic asthma in children (55, 56). This supports the hypothesis that early-life
428 chemical exposure may contribute to airway inflammation independent of IgE-mediated mechanisms.
429

430 There is also evidence suggesting that phthalates may induce a mixed inflammatory response. The
431 Hokkaido study found that phthalate exposure in children aged 9–12 years was associated with both
432 type 2 (eosinophilic) and non-type 2 (neutrophilic) inflammation biomarkers (57). Similarly, a
433 Taiwanese adult case-control study reported associations between DEHP metabolites and both
434 atopic and non-atopic asthma (58). In our study, associations between postnatal exposure to
435 individual phthalates and asthma did not differ substantially by atopic status. Atopic asthma is often
436 driven by Th2-mediated eosinophilic inflammation, whereas non-atopic asthma is more often
437 associated with Th17-dominant neutrophilic inflammation (59). Animal studies have shown that
438 phthalates can activate the p38 MAPK signalling pathway, leading to increased oxidative stress and
439 a mixed Th2/Th17 immune response (60). This pathway is negatively regulated by estrogen receptor
440 beta (ER_{β}), which exerts anti-proliferative effects on airway smooth muscle (61). Given that
441 phthalates are estrogenic and anti-estrogenic xenobiotics (62, 63), these compounds may disrupt
442 ER_{β} signalling, leading to p38 MAPK activation and subsequent mixed Th2/Th17-mediated airway
443 inflammation.
444
445 The distinct dose-response patterns observed for atopic versus non-atopic asthma, however,
446 suggest potentially different mechanisms between phenotypes. The U-shaped association for atopic
447 asthma is consistent with the non-linear dose-response relationships that are possible for endocrine-
448 disrupting chemicals (64). The Maternal-Infant Research on Environmental Chemicals Study, for
449 instance, reported an inverted U-shaped association between maternal MCPP concentrations and
450 cord blood IgE levels (65). These findings support the notion that phthalates may influence immune
451 development through nonlinear effects. Non-monotonic dose-response patterns have been
452 described in hormonal pathways affected by phthalates (64), such as estrogen and androgen
453 signalling, which may explain the male-specific associations with atopic asthma observed in earlier
454 studies (10, 51). In contrast, the linear associations we observed for non-atopic asthma may reflect
455 a dose-dependent increase in oxidative stress (66), which has been implicated in Th17 neutrophilic
456 inflammation (67).
457

458 Due to the low detection frequencies of maternal bisphenols, our ability to assess their associations
459 with respiratory and allergic outcomes was limited. Nonetheless, we found that prenatal exposure to
460 BPF was more strongly associated with atopic wheeze and increased airway resistance in atopic
461 children. Although mechanistic evidence specific to BPF and atopic outcomes remains limited, BPF
462 has estrogenic activity (68), which may promote a Th2 immune response (69). Experimental studies
463 have also shown that gestational and lactational exposure to BPF can induce airway eosinophilic
464 inflammation and cellular infiltration in female offspring, potentially through disruption of redox
465 homeostasis and immunosuppressive pathways (70).
466
467 We also found that prenatal exposure to phthalate mixtures was associated with a lower FRC in non-
468 atopic children, consistent with a paradigm of lower lung volumes predisposing to symptomatic lung
469 disease in non-atopic children (71). In contrast, increased FRC in atopic children may indicate air
470 trapping due to small airway obstruction (71). However, these findings need to be confirmed with
471 more sensitive methods for assessing static lung volumes, such as whole-body plethysmography.
472 Although the observed reductions in airway resistance associated with prenatal phthalate mixture
473 exposure among atopic children seem contradictory, the presence of non-monotonic dose-response
474 relationships observed in this study suggests heterogeneous effects across exposure levels. Further
475 studies are needed to understand how early-life chemical exposure influences respiratory mechanics
476 in developing lungs.
477
478 The inverse associations observed between prenatal exposure to phthalates or bisphenols and
479 allergic outcomes, including food allergy, are unlikely to be causal. There is no biological basis to
480 suggest that prenatal phthalates and bisphenols protect against allergic conditions. These findings
481 could be the result of unmeasured confounding or chance findings. Replication in larger cohorts is
482 warranted to clarify these associations.
483
484 This study has important strengths. We examined both prenatal and postnatal exposure windows,
485 and used objective outcome measures, including skin prick testing, lung function assessments, and
486 oral food challenge, which is the gold standard for diagnosing IgE-mediated food allergies (52). The

487 inclusion of two population-based birth cohorts enhances the generalisability of our findings to high-
488 income, English-speaking settings. However, several limitations should be acknowledged. First,
489 phthalates and bisphenols have short biological half-lives and are eliminated within 24–48 hours (72).
490 Thus, single-spot urine samples may not accurately reflect long-term exposure and could result in
491 nondifferential misclassification, biasing estimates toward the null. In contrast, childhood
492 measurements were taken at widely spaced intervals, and we averaged concentrations across three
493 time points to better represent overall early-childhood exposure. However, this approach may have
494 hidden specific windows of vulnerability. Furthermore, the lack of time-of-day data for urine collection
495 in CHILD may have introduced further misclassification. Second, differences in outcome
496 ascertainment between cohorts limited direct comparability. In BIS, allergic outcomes were primarily
497 parent-reported and susceptible to overreporting and non-differential outcome misclassification bias.
498 In contrast, CHILD relied on physician diagnoses, which may explain the lower prevalence of allergic
499 outcomes. A smaller proportion of atopic children in CHILD may have limited statistical power to
500 detect modest associations, particularly in subgroups related to lung function. Third, while skin prick
501 testing provides an objective measure of sensitisation, it may not capture the full heterogeneity of
502 allergic phenotypes. For example, some children with a local airway Th2-immune response may test
503 negative on SPT despite underlying eosinophilic inflammation (73). Future studies should consider
504 more granular phenotyping approaches, such as molecular analysis of nasal epitheliums or induced
505 sputum. Finally, lung function measurements were conducted when children were asymptomatic,
506 which may have underestimated the presence or severity of airway dysfunction associated with
507 environmental exposures.
508
509 In summary, exposure to phthalates during late pregnancy and early childhood may differentially
510 influence asthma phenotypes at preschool age, with limited evidence for consistent associations with
511 other allergic outcomes. Future studies should incorporate more granular phenotyping approaches
512 to characterise underlying mechanisms. In addition, greater harmonisation of outcome definitions
513 across cohorts is needed to enable direct comparisons and strengthen causal inference in future
514 studies.

CRediT authorship contribution statement

Thomas Boissiere-O'Neill: Conceptualisation, Methodology, Formal analysis Writing – original draft. **Nina Lazarevic**: Conceptualisation, Methodology, Writing – review and editing. **Anne-Louise Ponsonby**: Conceptualisation, Methodology, Writing – review and editing. **Peter D. Sly**: Conceptualisation, Writing – review and editing. **Aimin Chen**: Conceptualisation, Writing – review and editing. **Tamara L. Blake**: Writing – review and editing. **Jeffrey R. Brook**: Writing – review and editing. **Cassidy Du Berry**: Validation, Writing – review and editing. **Louise King**: Validation, Writing – review and editing**. Piushkumar J. Mandhane**: Writing – review and editing. **Theo J. Moraes**: Writing – review and editing. **Elinor Simons**: Writing – review and editing. **Padmaja Subbarao**: Writing – review and editing. **Dwan Vilcins**: Supervision, Conceptualisation, Methodology, Writing – review and editing.

Data statement

The data that support the findings of this study are not openly available due to reasons of sensitivity and are available from childstudy.ca and barwoninfantstudy.org.au

Funding

TBON was supported by an Australian Government Research Training Program (RTP) Scholarship and a small grant award from the University of Queensland—Child Health Research Centre. PDS is a leadership Fellow (L3) of the National Health and Medical Research Council.

Declaration of competing interests

The authors declare that they have no competing interests.

Acknowledgements

We thank the CHILD Cohort Study (CHILD) participant families for their dedication and commitment to advancing health research. CHILD was initially funded by CIHR and AllerGen NCE. Visit CHILD at childstudy.ca. We thank the BIS participants for the generous contribution they have made to this project. We also thank current and past staff for their efforts in recruiting and maintaining the cohort and in obtaining and processing the data and biospecimens. The establishment work and infrastructure for the BIS was provided by the Murdoch Children's Research Institute, Deakin University and Barwon Health. Subsequent funding was secured from the National Health and Medical Research Council of Australia, The Jack Brockhoff Foundation, the Scobie Trust, the Shane O'Brien Memorial Asthma Foundation, the OurWomen's Our Children's Fund Raising Committee Barwon Health, The Shepherd Foundation, the Rotary Club of Geelong, the Ilhan Food Allergy Foundation, GMHBA Ltd, The Gandel Foundation, The Percy Baxter Charitable Trust, Perpetual Trustees and the Gwenyth Raymond Trust. Vanguard Investments Australia Ltd provided funding for analysis of plasticizers in biospecimens. In-kind support was provided by the Cotton On Foundation and CreativeForce. Research at Murdoch Children's Research Institute is supported by the Victorian Government's Operational Infrastructure Support Program.

553 **REFERENCES**

554 1. Foppiano F, Schaub B. Childhood asthma phenotypes and endotypes: a glance into
555 the mosaic. Molecular and Cellular Pediatrics. 2023;10(1):9.

556 2. Kusel MMH, Holt PG, de Klerk N, Sly PD. Support for 2 variants of eczema. Journal
557 of Allergy and Clinical Immunology. 2005;116(5):1067-72.

558 3. Pearce N, Pekkanen J, Beasley R. How much asthma is really attributable to atopy?
559 Thorax. 1999;54(3):268.

560 4. Bølling AK, Sripada K, Becher R, Bekö G. Phthalate exposure and allergic diseases:
561 Review of epidemiological and experimental evidence. Environment international.
562 2020;139:105706.

563 5. Wang Y, Zhu H, Kannan K. A Review of Biomonitoring of Phthalate Exposures.
564 Toxics. 2019;7(2):21.

565 6. Robinson L, Miller R. The Impact of Bisphenol A and Phthalates on Allergy, Asthma,
566 and Immune Function: a Review of Latest Findings. Curr Environ Health Rep.
567 2015;2(4):379-87.

568 7. Li M-C, Chen C-H, Guo YL. Phthalate esters and childhood asthma: A systematic
569 review and congener-specific meta-analysis. Environmental Pollution. 2017;229:655-60.

570 8. Xie M-Y, Ni H, Zhao D-S, Wen L-Y, Li K-S, Yang H-H, et al. Exposure to bisphenol A
571 and the development of asthma: A systematic review of cohort studies. Reproductive
572 Toxicology. 2016;65:224-9.

573 9. Zhang H, Chen S, Chen X, Zhang Y, Han Y, Li J, et al. Exposure to phthalate
574 increases the risk of eczema in children: Findings from a systematic review and meta-
575 analysis. Chemosphere. 2023;321:138139.

576 10. Soomro Munawar H, Baiz N, Philippat C, Vernet C, Siroux V, Nichole Maesano C, et
577 al. Prenatal Exposure to Phthalates and the Development of Eczema Phenotypes in Male
578 Children: Results from the EDEN Mother–Child Cohort Study. Environmental Health
579 Perspectives. 2018;126(2):027002.

580 11. Lee JY, Lee J, Huh DA, Moon KW. Association between environmental exposure to
581 phthalates and allergic disorders in Korean children: Korean National Environmental Health
582 Survey (KoNEHS) 2015–2017. International Journal of Hygiene and Environmental Health.
583 2021;238.

584 12. Wang IJ, Chen CY, Bornehag CG. Bisphenol A exposure may increase the risk of
585 development of atopic disorders in children. International Journal of Hygiene and
586 Environmental Health. 2016;219(3):311-6.

587 13. Ducharme FM, Dell SD, Radhakrishnan D, Grad RM, Watson WTA, Yang CL, et al.
588 Diagnosis and management of asthma in preschoolers: A Canadian Thoracic Society and
589 Canadian Paediatric Society position paper. Paediatrics & Child Health. 2015;20(7):353-61.

590 14. Boissiere-O'Neill T, Lee WR, Blake TL, Sly PD, Vilcins D. Exposure to endocrine-
591 disrupting plasticisers and lung function in children and adolescents: A systematic review
592 and meta-analysis. Environmental research. 2024;243:117751.

15. Westrupp N, Berry CD, Cole T, Shanthikumar S, Welsh L. Detection of Bronchiolitis Obliterans Syndrome Using Nitrogen Multiple Breath Washout in Children Posthemopoietic Stem Cell Transplant. Transplantation and Cellular Therapy. 2024;30(5):524.e1-.e9.

16. Crenesse D, Berlioz M, Bourrier T, Albertini M. Spirometry in children aged 3 to 5 years: Reliability of forced expiratory maneuvers. Pediatric Pulmonology. 2001;32(1):56-61.

17. Aurora P, Stocks J, Oliver C, Saunders C, Castle R, Chaziparasidis G, et al. Quality Control for Spirometry in Preschool Children with and without Lung Disease. American Journal of Respiratory and Critical Care Medicine. 2004;169(10):1152-9.

18. Vuillermin P, Saffery R, Allen KJ, Carlin JB, Tang ML, Ranganathan S, et al. Cohort Profile: The Barwon Infant Study. International Journal of Epidemiology. 2015;44(4):1148-60.

19. Subbarao P, Anand SS, Becker AB, Befus AD, Brauer M, Brook JR, et al. The Canadian Healthy Infant Longitudinal Development (CHILD) Study: examining developmental origins of allergy and asthma. Thorax. 2015;70(10):998.

20. Sugeng EJ, Symeonides C, O'Hely M, Vuillermin P, Sly PD, Vijayasarathy S, et al. Predictors with regard to ingestion, inhalation and dermal absorption of estimated phthalate daily intakes in pregnant women: The Barwon infant study. Environment international. 2020;139:105700.

21. Navaranjan G, Takaro TK, Wheeler AJ, Diamond ML, Shu H, Azad MB, et al. Early life exposure to phthalates in the Canadian Healthy Infant Longitudinal Development (CHILD) study: a multi-city birth cohort. Journal of Exposure Science & Environmental Epidemiology. 2020;30(1):70-85.

22. Heffernan AL, Gomez-Ramos MJ, Symeonides C, Hare DJ, Vijayasarathy S, Thompson K, et al. Harmonizing analytical chemistry and clinical epidemiology for human biomonitoring studies. A case-study of plastic product chemicals in urine. Chemosphere. 2020;238:124631.

23. Kato K, Silva MJ, Needham LL, Calafat AM. Determination of 16 Phthalate Metabolites in Urine Using Automated Sample Preparation and On-line Preconcentration/High-Performance Liquid Chromatography/Tandem Mass Spectrometry. Analytical Chemistry. 2005;77(9):2985-91.

24. Symeonides C, Vacy K, Thomson S, Tanner S, Chua HK, Dixit S, et al. Male autism spectrum disorder is linked to brain aromatase disruption by prenatal BPA in multimodal investigations and 10HDA ameliorates the related mouse phenotype. Nature Communications. 2024;15(1):6367.

25. Heffernan AL, Aylward LL, Toms LML, Eaglesham G, Hobson P, Sly PD, et al. Age-Related Trends in Urinary Excretion of Bisphenol A in Australian Children and Adults: Evidence from a Pooled Sample Study Using Samples of Convenience. Journal of Toxicology and Environmental Health, Part A. 2013;76(18):1039-55.

26. Calafat AM, Silva MJ, Reidy JA, Earl Gray L, Samandar E, Preau Jr JL, et al. Mono-(3-Carboxypropyl) Phthalate, A Metabolite of Di-n-Octyl Phthalate. Journal of Toxicology and Environmental Health, Part A. 2006;69(3):215-27.

27. Gray LEK, Ponsonby A-L, Collier F, O'Hely M, Sly PD, Ranganathan S, et al. Deserters on the atopic march: Risk factors, immune profile and clinical outcomes of food sensitized–tolerant infants. Allergy. 2020;75(6):1404-13.

636 28. WILLIAMS HC, JBURNEY PG, PEMBROKE AC, HAY RJ, Party ADDCW. The U.K.
637 Working Party's Diagnostic Criteria for Atopic Dermatitis. III. Independent hospital validation.
638 British Journal of Dermatology. 1994;131(3):406-16.

639 29. Dharma C, Lefebvre DL, Tran MM, Lu Z, Lou WYW, Subbarao P, et al. Diagnosing
640 atopic dermatitis in infancy: Questionnaire reports vs criteria-based assessment. Paediatric
641 and Perinatal Epidemiology. 2018;32(6):556-67.

642 30. Robinson PD, Latzin P, Ramsey KA, Stanojevic S, Aurora P, Davis SD, et al.
643 Preschool Multiple-Breath Washout Testing. An Official American Thoracic Society
644 Technical Statement. American Journal of Respiratory and Critical Care Medicine.
645 2018;197(5):e1-e19.

646 31. Robinson PD, Latzin P, Verbanck S, Hall GL, Horsley A, Gappa M, et al. Consensus
647 statement for inert gas washout measurement using multiple- and single- breath tests.
648 European Respiratory Journal. 2013;41(3):507-22.

649 32. Song TW, Kim KW, Kim ES, Park J-W, Sohn MH, Kim K-E. Utility of impulse
650 oscillometry in young children with asthma. Pediatric Allergy and Immunology.
651 2008;19(8):763-8.

652 33. Wyler F, Oestreich M-A, Frauchiger BS, Ramsey KA, Latzin P. Correction of sensor
653 crosstalk error in Exhalyzer D multiple-breath washout device significantly impacts outcomes
654 in children with cystic fibrosis. Journal of Applied Physiology. 2021;131(3):1148-56.

655 34. Sly PD, Hantos Z. The International Collaboration to Improve Respiratory Health in
656 Children (INCIRCLE) ERS Clinical Research Collaboration. European Respiratory Journal.
657 2018;52(6):1801867.

658 35. Hantos Z. Intra-breath oscillometry for assessing respiratory outcomes. Current
659 Opinion in Physiology. 2021;22:100441.

660 36. Australian Bureau of Statistics. 2033.0.55.001 - Census of Population and Housing:
661 Socio-Economic Indexes for Areas (SEIFA), Australia, 2016 2018 [Available from:
662 https://www.abs.gov.au/ausstats/abs@.nsf/mf/2033.0.55.001.

663 37. Maugeri A, Barchitta M, Agrifoglio O, Favara G, La Mastra C, La Rosa MC, et al. The
664 impact of social determinants and lifestyles on dietary patterns during pregnancy: evidence
665 from the "Mamma & Bambino" study. Annali di Igiene : Medicina Preventiva e di Comunita.
666 2019;31(2 Supple 1):81-9.

667 38. Sherriff A, Farrow A, Golding J, Henderson J. Frequent use of chemical household
668 products is associated with persistent wheezing in pre-school age children. Thorax.
669 2005;60(1):45.

670 39. Jakobsen JC, Gluud C, Wetterslev J, Winkel P. When and how should multiple
671 imputation be used for handling missing data in randomised clinical trials – a practical guide
672 with flowcharts. BMC Medical Research Methodology. 2017;17(1):162.

673 40. Harrell FE. General Aspects of Fitting Regression Models. In: Harrell JFE, editor.
674 Regression Modeling Strategies: With Applications to Linear Models, Logistic and Ordinal
675 Regression, and Survival Analysis. Cham: Springer International Publishing; 2015. p. 13-44.

41. Ponsonby A-L. Reflection on modern methods: building causal evidence within high-dimensional molecular epidemiological studies of moderate size. International Journal of Epidemiology. 2021;50(3):1016-29.

42. Zou G. A Modified Poisson Regression Approach to Prospective Studies with Binary Data. American Journal of Epidemiology. 2004;159(7):702-6.

43. Pekkanen J, Lampi J, Genuneit J, Hartikainen A-L, Järvelin M-R. Analyzing atopic and non-atopic asthma. European Journal of Epidemiology. 2012;27(4):281-6.

44. Arel-Bundock V. marginaleffects: Predictions, Comparisons, Slopes, Marginal Means, and Hypothesis Tests. 0.17.0 ed2023.

45. Keil Alexander P, Buckley Jessie P, O'Brien Katie M, Ferguson Kelly K, Zhao S, White Alexandra J. A Quantile-Based g-Computation Approach to Addressing the Effects of Exposure Mixtures. Environmental Health Perspectives.128(4):047004.

46. Keil A. qgcompint: Quantile G-Computation Extensions for Effect Measure Modification. 1.0.0 ed. CRAN2025.

47. Bobb JF, Valeri L, Claus Henn B, Christiani DC, Wright RO, Mazumdar M, et al. Bayesian kernel machine regression for estimating the health effects of multi-pollutant mixtures. Biostatistics. 2014;16(3):493-508.

48. Florsheim EB, Bachtel ND, Cullen JL, Lima BGC, Godazgar M, Carvalho F, et al. Immune sensing of food allergens promotes avoidance behaviour. Nature. 2023;620(7974):643-50.

49. Simpson A, Custovic A. Pets and the development of allergic sensitization. Current Allergy and Asthma Reports. 2005;5(3):212-20.

50. Ponsonby A-L, Dwyer T, Kemp A, Lim L, Cochrane J, Carmichael A. The use of mutually exclusive categories for atopic sensitization: A contrasting effect for family size on house dust mite sensitization compared with ryegrass sensitization. Pediatric Allergy and Immunology. 2003;14(2):81-90.

51. Gómez-Olarte S, Röder S, Rolle-Kampczyk U, Sack U, von Bergen M, Borte M, et al. Prenatal exposure to mixtures of phthalates and bisphenol A and eczema risk: findings in atopic and non-atopic children from the LiNA birth cohort. Environmental research. 2025;278:121667.

52. Riggioni C, Ricci C, Moya B, Wong D, van Goor E, Bartha I, et al. Systematic review and meta-analyses on the accuracy of diagnostic tests for IgE-mediated food allergy. Allergy. 2024;79(2):324-52.

53. Dodson Robin E, Nishioka M, Standley Laurel J, Perovich Laura J, Brody Julia G, Rudel Ruthann A. Endocrine Disruptors and Asthma-Associated Chemicals in Consumer Products. Environmental Health Perspectives. 2012;120(7):935-43.

54. Henderson J, Sherriff A, Farrow A, Ayres JG. Household chemicals, persistent wheezing and lung function: effect modification by atopy? European Respiratory Journal. 2008;31(3):547.

715 55. Sevelsted A, Pedersen C-ET, Gürdeniz G, Rasmussen MA, Schullehner J, Sdougkou
716 K, et al. Exposures to perfluoroalkyl substances and asthma phenotypes in childhood: an
717 investigation of the COPSAC2010 cohort. eBioMedicine. 2023;94.

718 56. Karimi P, Peters KO, Bidad K, Strickland PT. Polycyclic aromatic hydrocarbons and
719 childhood asthma. European Journal of Epidemiology. 2015;30(2):91-101.

720 57. Ketema RM, Ait Bamai Y, Goudarzi H, Yamaguchi T, Zeng Y, Yasuda A, et al.
721 Association of Phthalate Exposure with Respiratory and Allergic Symptoms and Type 2 and
722 Non-Type 2 Inflammation: The Hokkaido Study. Environmental Science & Technology.
723 2025;59(15):7541-9.

724 58. Hsu Y-T, Wu C-C, Wang C-C, Sheu C-C, Yang Y-H, Cheng M-Y, et al. Increased di-
725 (2-ethylhexyl) phthalate exposure poses a differential risk for adult asthma clusters.
726 Respiratory Research. 2024;25(1):139.

727 59. Kuruvilla ME, Lee FE-H, Lee GB. Understanding Asthma Phenotypes, Endotypes,
728 and Mechanisms of Disease. Clinical Reviews in Allergy & Immunology. 2019;56(2):219-33.

729 60. Qin W, Deng T, Cui H, Zhang Q, Liu X, Yang X, et al. Exposure to diisodecyl
730 phthalate exacerbated Th2 and Th17-mediated asthma through aggravating oxidative stress
731 and the activation of p38 MAPK. Food and Chemical Toxicology. 2018;114:78-87.

732 61. Ambhore NS, Katragadda R, Raju Kalidhindi RS, Thompson MA, Pabelick CM,
733 Prakash YS, et al. Estrogen receptor beta signaling inhibits PDGF induced human airway
734 smooth muscle proliferation. Molecular and Cellular Endocrinology. 2018;476:37-47.

735 62. Kiyama R, Wada-Kiyama Y. Estrogenic endocrine disruptors: Molecular mechanisms
736 of action. Environment international. 2015;83:11-40.

737 63. Okubo T, Suzuki T, Yokoyama Y, Kano K, Kano I. Estimation of Estrogenic and Anti-
738 estrogenic Activities of Some Phthalate Diesters and Monoesters by MCF-7 Cell Proliferation
739 Assay in Vitro. Biological and Pharmaceutical Bulletin. 2003;26(8):1219-24.

740 64. Vandenberg LN, Colborn T, Hayes TB, Heindel JJ, Jacobs DR, Jr., Lee D-H, et al.
741 Hormones and Endocrine-Disrupting Chemicals: Low-Dose Effects and Nonmonotonic Dose
742 Responses. Endocrine Reviews. 2012;33(3):378-455.

743 65. Ashley-Martin J, Dodds L, Levy AR, Platt RW, Marshall JS, Arbuckle TE. Prenatal
744 exposure to phthalates, bisphenol A and perfluoroalkyl substances and cord blood levels of
745 IgE, TSLP and IL-33. Environmental research. 2015;140:360-8.

746 66. Liao Q, Huang H, Zhang X, Ma X, Peng J, Zhang Z, et al. Assessment of health risk
747 and dose-effect of DNA oxidative damage for the thirty chemicals mixture of parabens,
748 triclosan, benzophenones, and phthalate esters. Chemosphere. 2022;308:136394.

749 67. Abimannan T, Peroumal D, Parida JR, Barik PK, Padhan P, Devadas S. Oxidative
750 stress modulates the cytokine response of differentiated Th17 and Th1 cells. Free Radical
751 Biology and Medicine. 2016;99:352-63.

752 68. Moreman J, Lee O, Trznadel M, David A, Kudoh T, Tyler CR. Acute Toxicity,
753 Teratogenic, and Estrogenic Effects of Bisphenol A and Its Alternative Replacements
754 Bisphenol S, Bisphenol F, and Bisphenol AF in Zebrafish Embryo-Larvae. Environmental
755 Science & Technology. 2017;51(21):12796-805.

69. Cai Y, Zhou J, Webb DC. Estrogen Stimulates Th2 Cytokine Production and Regulates the Compartmentalisation of Eosinophils during Allergen Challenge in a Mouse Model of Asthma. International Archives of Allergy and Immunology. 2012;158(3):252-60.

70. Du J, Huo S, Li B, Zhang X, Zhang J, Fu Y, et al. The toxic effects and mechanisms of maternal exposure to Bisphenol F during gestation and lactation on lungs in female offspring mice. Environmental Pollution. 2024;361:124800.

71. Hopkins E, Sharma S. Physiology, Functional Residual Capacity: StatPearls Publishing; 2025 [Available from: https://www.ncbi.nlm.nih.gov/books/NBK500007/.

72. Johns LE, Cooper GS, Galizia A, Meeker JD. Exposure assessment issues in epidemiology studies of phthalates. Environment international. 2015;85:27-39.

73. Rondón C, Fernández J, López S, Campo P, Doña I, Torres MJ, et al. Nasal inflammatory mediators and specific IgE production after nasal challenge with grass pollen in local allergic rhinitis. Journal of Allergy and Clinical Immunology. 2009;124(5):1005-11.e1.